GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome
05. Januar 2022 08:00 ET
|
Ultragenyx Pharmaceutical Inc.; GeneTx Biotherapeutics LLC
SARASOTA, Fla. and NOVATO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102,...
GeneTx and Ultragenyx Announce Presentations at Upcoming 2021 FAST Global Summit & Gala
01. Dezember 2021 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
SARASOTA, Fla. and NOVATO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), companies partnered in the development of GTX-102,...
FAST and SFARI to launch International Angelman Syndrome Research Council (INSYNC-AS)
19. Februar 2021 09:00 ET
|
FAST (Foundation for Angelman Syndrome Therapeutics)
DOWNERS GROVE, Ill., Feb. 19, 2021 (GLOBE NEWSWIRE) -- FAST (Foundation for Angelman Syndrome Therapeutics) and the Simons Foundation Autism Research Initiative (SFARI) today announced a...
AskBio Enters Research Collaboration and Licensing Agreement with University of North Carolina (UNC) for Angelman Syndrome
18. März 2020 09:27 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. and CHAPEL HILL, N.C., March 18, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading clinical-stage adeno-associated virus (AAV) gene therapy...
Lixte Biotechnology’s PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental Disorder
25. Juni 2019 09:35 ET
|
Lixte Biotechnology Holdings, Inc.
EAST SETAUKET, NY, June 25, 2019 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) noted that a group of neuroscientists in China and Japan reported that Lixte’s lead clinical...
GeneTx Biotherapeutics receives FDA orphan-drug designation for Angelman syndrome treatment
27. März 2018 13:26 ET
|
GeneTx Biotherapeutics LLC.
DOWNERS GROVE, Ill., March 27, 2018 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration has granted orphan-drug designation to GeneTx Biotherapeutics LLC’s GTX-101 for the treatment of...